Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer

Citations Over Time

Abstract

Ixabepilone (Ixempra(®); Bristol-Myers Squibb) is a novel microtubule stabilizing agent recently approved for the treatment of metastatic breast cancer (MBC). This article focuses on considerations for ixabepilone administration and adverse event (AE) management, drawing from the biomedical literature indexed in PubMed, published abstracts from the American Society of Clinical Oncology annual meetings, and the manufacturer's prescribing information for ixabepilone. Administered as monotherapy or in combination with capecitabine in clinical studies, ixabepilone demonstrated positive clinical response rates, prolonged progression-free survival, and a favorable safety profile in patients with MBC. Treatment-related AEs were predictable and manageable with dose modification, treatment interruption, and active management. As ixabepilone undergoes development in earlier lines of breast cancer therapy and in other solid tumors, oncology nurses will encounter more and more patients receiving ixabepilone therapy. If nurses are acquainted with the unique management strategies associated with ixabepilone treatment, as detailed herein, patients are more likely to receive the full benefit of therapy.

Related Papers

• → Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies(2009)106 cited
• → Ixabepilone: a new microtubule-targeting agent for breast cancer(2008)4 cited
• → Identifying Subsets of Metastatic Breast Cancer Patients Likely to Benefit From Treatment With the Epothilone B Analog Ixabepilone(2010)2 cited
• → Long-Lasting Control of Triple-Negative Metastatic Breast Cancer with the Novel Drug Combination Ixabepilone and Capecitabine – Case Report(2010)2 cited
• → Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): Final report(2006)16 cited